IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Invivyd, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.61−0.01 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $195.47M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.1300 (−64.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Invivyd, Inc. grew revenue 26.3% to $58.37M over the twelve months to Jun 30, 2026. Free cash flow was -$109.66M.
Revenue
$58.37M
+26.3% vs. a year earlier
Operating income
-$112.53M
TTM Q2 2026
Free cash flow
-$109.66M
TTM Q2 2026
EPS, diluted
-$0.37
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $195.47M
- P/E ratio
- –
- Price to sales
- 3.35
- Price to book
- 1.08
- Dividend yield
- –
- Free cash flow yield
- -56.10%
Fundamentals
- Revenue
- $58.37M
- Net income
- -$107.33M
- EPS, diluted
- -$0.37
- Free cash flow
- -$109.66M
- Book value per share
- $0.57
- Diluted shares
- 320M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$58.37M+26.3% YoY
Operating income
-$112.53M
Net income
-$107.33M
EPS, diluted
-$0.37
Free cash flow
-$109.66M
Reported periodTrailing twelve months